Literature DB >> 15642321

Matrix metalloproteinases are down-regulated in rat lenses exposed to oxidative stress.

Molykutty John1, Cynthia Jaworski, Zhengguang Chen, Saradha Subramanian, Wanchao Ma, Fang Sun, Dayu Li, Abraham Spector, Deborah Carper.   

Abstract

Matrix metalloproteinases are important biological effectors of tissue remodelling. Increased MMP expression occurs during injury, inflammation, cellular transformation, and oxidative stress. Oxidative stress in the lens, a causal factor in cataractogenesis, has been shown to induce MMP secretion. The objective of this study was to assess the expression of MMPs and their regulators in an oxidative stress model of cataract, where epithelial cell death and cortical fibre cell swelling occurs in rat lenses after exposure to riboflavin, oxygen, and light. Two time points (4 and 7 hr of exposure) were chosen in order to compare transparent lenses with partially opaque lenses. MMP activity, protein, and mRNA levels were measured. The results show that MMP-2, MMP-9, MT1-MMP, and MT3-MMP are down-regulated by oxidative stress and that the down-regulation is most likely due to reduced gene transcription. In contrast, genes for catalase, glutathione peroxidase, and GAPDH are essentially unaffected, while beta-actin mRNA and protein levels are markedly increased at both time points. The down-regulation of MMPs occurs in lenses still seemingly transparent after 4 hr of exposure, indicating that reduced MMP activity is a relatively early response to the oxidative stress. Moreover, in our model system, MMP inhibition, not induction, is associated with cataractogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15642321     DOI: 10.1016/j.exer.2004.08.025

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  8 in total

1.  Long-term alcohol consumption increases pro-matrix metalloproteinase-9 levels via oxidative stress.

Authors:  Tulay Koken; Fatih Gursoy; Ahmet Kahraman
Journal:  J Med Toxicol       Date:  2010-06

2.  Matrix metalloproteinase inhibitors suppress transforming growth factor-beta-induced subcapsular cataract formation.

Authors:  Dhruva J Dwivedi; Giuseppe Pino; Alice Banh; Zahra Nathu; Derek Howchin; Peter Margetts; Jacob G Sivak; Judith A West-Mays
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

3.  Matrix metalloproteinase-9-null mice are resistant to TGF-β-induced anterior subcapsular cataract formation.

Authors:  Anna Korol; Giuseppe Pino; Dhruva Dwivedi; Jennifer V Robertson; Paula A Deschamps; Judith A West-Mays
Journal:  Am J Pathol       Date:  2014-05-06       Impact factor: 4.307

4.  Metalloproteinase's activity and oxidative stress in mild cognitive impairment and Alzheimer's disease.

Authors:  Sagrario Martín-Aragón; Paloma Bermejo-Bescós; Juana Benedí; Emanuela Felici; Pedro Gil; José Manuel Ribera; Angel Ma Villar
Journal:  Neurochem Res       Date:  2008-07-10       Impact factor: 3.996

5.  Downregulation of MMP-2 and -9 by proteasome inhibition: a possible mechanism to decrease LEC migration and prevent posterior capsular opacification.

Authors:  Niranjan Awasthi; Shuh Tuan Wang-Su; B J Wagner
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05       Impact factor: 4.799

6.  Matrix Metalloproteinases as Mediators of Primary and Secondary Cataracts.

Authors:  Judith A West-Mays; Giuseppe Pino
Journal:  Expert Rev Ophthalmol       Date:  2007

7.  Particle radiation alters expression of matrix metalloproteases resulting in ECM remodeling in human lens cells.

Authors:  P Y Chang; K A Bjornstad; C J Rosen; S Lin; E A Blakely
Journal:  Radiat Environ Biophys       Date:  2007-01-26       Impact factor: 2.017

8.  Bone repair in craniofacial defects treated with different doses of alendronate: a histological, histomorphometric, and immunohistochemical study.

Authors:  Naylin de Oliveira; Jefferson Oliveira; Letícia de Souza Moraes; Suyany Gabriely Weiss; Luís Henrique Chaves; Thais Costa Casagrande; Tatiana Miranda Deliberador; Allan Fernando Giovanini; João César Zielak; Rafaela Scariot
Journal:  Clin Oral Investig       Date:  2018-10-09       Impact factor: 3.573

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.